mRNA疫苗接种与COVID-19住院及疾病严重程度的关联
该研究为美国21中心病例对照分析,纳入4513例住院成人,其中1983例COVID-19病例与2530例非COVID-19对照。接种mRNA疫苗与COVID-19住院风险降低相关(aOR 0.15,95%CI 0.13-0.18),在免疫抑制患者中关联较弱(aOR 0.49),BNT162b2接种超过120天后关联减弱(aOR 0.36)。在1197例COVID-19住院患者中,接种与28天内死亡或侵袭性机械通气风险降低相关(aOR 0.33,95%CI 0.19-0.58)。结果支持突破性感染较未接种者疾病严重程度更低。
要点
- 未接种者占COVID-19住院的84.2%(1669/1983),接种与住院风险降低独立相关(aOR 0.15,95%CI 0.13-0.18)。
- BNT162b2接种超过120天后与住院的关联减弱(aOR 0.36,95%CI 0.27-0.49),mRNA-1273为aOR 0.15(95%CI 0.09-0.23)。
- 在COVID-19住院患者中,接种与28天内死亡或侵袭性机械通气风险降低相关(aOR 0.33,95%CI 0.19-0.58)。
- 对Alpha和Delta变异株,接种与住院风险降低的关联均显著(aOR分别为0.10和0.14)。
适用人群与场景
- 2021年3月11日至8月15日在美国21个中心住院的成人(中位年龄59岁,48.8%女性),包括COVID-19病例和非COVID-19对照。
- 免疫抑制患者占20.1%,免疫正常患者中接种与住院关联更强。
- 研究纳入住院患者,不涉及院前或门诊人群。
诊断标准与关键阈值
- COVID-19住院病例定义为因COVID-19住院的患者,对照为因其他诊断住院的患者。
- 疾病进展定义为住院COVID-19患者28天内死亡或接受侵袭性机械通气。
- 疫苗接种状态依据mRNA-1273或BNT162b2接种史,未提及具体接种间隔阈值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:美国21中心病例对照分析,纳入4513例住院成人(1983例COVID-19病例,2530例对照)。
- 主要终点:接种与COVID-19住院风险降低相关(病例接种率15.8% vs 对照54.8%;aOR 0.15,95%CI 0.13-0.18)。
- 变异株:Alpha(aOR 0.10,95%CI 0.06-0.16)和Delta(aOR 0.14,95%CI 0.10-0.21)均显示关联。
- 住院患者中,接种与28天内死亡或侵袭性机械通气风险降低相关(12.0% vs 24.7%;aOR 0.33,95%CI 0.19-0.58)。
证据类型、等级与局限
- 证据类型:多中心病例对照分析(21中心),非随机对照试验。
- 局限:观察性设计,可能存在残余混杂;仅纳入住院患者;免疫抑制状态为自我报告或病历记录;未提及具体疫苗推荐等级。
对床旁实践的改变
- 支持mRNA疫苗接种作为降低COVID-19住院和重症风险的措施,尤其对免疫正常人群。
- 免疫抑制患者接种后仍需警惕突破性感染住院风险,关联强度较弱(aOR 0.49)。
- BNT162b2接种超过120天后与住院的关联减弱,提示需关注疫苗保护随时间衰减,但原文未提及加强针建议。
- 不改变对未接种者的重症救治流程,但提示接种史应纳入住院COVID-19患者风险评估。
指南或共识出处
- 原文未提及指南或共识名称,仅引用研究本身。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A comprehensive understanding of the benefits of COVID-19 vaccination requires consideration of disease attenuation, determined as whether people who develop COVID-19 despite vaccination have lower disease severity than unvaccinated people.
OBJECTIVE: To evaluate the association between vaccination with mRNA COVID-19 vaccines-mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech)-and COVID-19 hospitalization, and, among patients hospitalized with COVID-19, the association with progression to critical disease.
DESIGN, SETTING, AND PARTICIPANTS: A US 21-site case-control analysis of 4513 adults hospitalized between March 11 and August 15, 2021, with 28-day outcome data on death and mechanical ventilation available for patients enrolled through July 14, 2021. Date of final follow-up was August 8, 2021.
EXPOSURES: COVID-19 vaccination.
MAIN OUTCOMES AND MEASURES: Associations were evaluated between prior vaccination and (1) hospitalization for COVID-19, in which case patients were those hospitalized for COVID-19 and control patients were those hospitalized for an alternative diagnosis; and (2) disease progression among patients hospitalized for COVID-19, in which cases and controls were COVID-19 patients with and without progression to death or mechanical ventilation, respectively. Associations were measured with multivariable logistic regression.
RESULTS: Among 4513 patients (median age, 59 years [IQR, 45-69]; 2202 [48.8%] women; 23.0% non-Hispanic Black individuals, 15.9% Hispanic individuals, and 20.1% with an immunocompromising condition), 1983 were case patients with COVID-19 and 2530 were controls without COVID-19. Unvaccinated patients accounted for 84.2% (1669/1983) of COVID-19 hospitalizations. Hospitalization for COVID-19 was significantly associated with decreased likelihood of vaccination (cases, 15.8%; controls, 54.8%; adjusted OR, 0.15; 95% CI, 0.13-0.18), including for sequenced SARS-CoV-2 Alpha (8.7% vs 51.7%; aOR, 0.10; 95% CI, 0.06-0.16) and Delta variants (21.9% vs 61.8%; aOR, 0.14; 95% CI, 0.10-0.21). This association was stronger for immunocompetent patients (11.2% vs 53.5%; aOR, 0.10; 95% CI, 0.09-0.13) than immunocompromised patients (40.1% vs 58.8%; aOR, 0.49; 95% CI, 0.35-0.69) (P < .001) and weaker at more than 120 days since vaccination with BNT162b2 (5.8% vs 11.5%; aOR, 0.36; 95% CI, 0.27-0.49) than with mRNA-1273 (1.9% vs 8.3%; aOR, 0.15; 95% CI, 0.09-0.23) (P < .001). Among 1197 patients hospitalized with COVID-19, death or invasive mechanical ventilation by day 28 was associated with decreased likelihood of vaccination (12.0% vs 24.7%; aOR, 0.33; 95% CI, 0.19-0.58).
CONCLUSIONS AND RELEVANCE: Vaccination with an mRNA COVID-19 vaccine was significantly less likely among patients with COVID-19 hospitalization and disease progression to death or mechanical ventilation. These findings are consistent with risk reduction among vaccine breakthrough infections compared with absence of vaccination.
参考来源
- Tenforde, Self, Adams, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021. PMID: 34734975. doi:10.1001/jama.2021.19499
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。